RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer

Receptor activator of NF-κB ligand (RANKL) and its receptor RANK, are members of the tumor necrosis factor and receptor superfamilies, respectively. Antibodies targeting RANKL have recently been evaluated in combination with anti-CTLA4 in case reports of human melanoma and mouse models of cancer. Ho...

Full description

Bibliographic Details
Main Authors: Elizabeth Ahern, Heidi Harjunpää, Jake S. O'Donnell, Stacey Allen, William C. Dougall, Michele W. L. Teng, Mark J. Smyth
Format: Article
Language:English
Published: Taylor & Francis Group 2018-06-01
Series:OncoImmunology
Subjects:
cd8+ t cells
metastasis
rank
rankl
tumors
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1431088

Internet

http://dx.doi.org/10.1080/2162402X.2018.1431088

Similar Items